PT-141 / Bremelanotide: Evidence and Safety
PT-141 (bremelanotide) is FDA-approved as Vyleesi, but only for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT phase 3 trial program. Using it for general “libido enhancement” outside that specific population and indication is off-label and far less studied; the evidence is Tier A only for the approved use.
Understand the mechanism A melanocortin-receptor agonist that acts centrally in the brain on the system that governs sexual desire, unlike PDE5 drugs that act on blood flow.
This is a different mechanism class from erectile-dysfunction drugs, which is why it targets desire rather than blood flow.
See what the approval actually covers FDA approved Vyleesi in June 2019 for hypoactive sexual desire disorder (HSDD) specifically in premenopausal women, based on the RECONNECT phase 3 trial program. Off-label use outside that population and indication is far less studied.
Rounding the approval up to general “libido enhancement” misrepresents what the trials actually tested.
Know where it stands FDA-approved (Vyleesi brand), prescription-only, dispensed as an autoinjector with a label-specified maximum frequency. Compounded or research-chemical “PT-141” sold outside that pathway is not the approved product.
The approval and its safety monitoring apply only to the branded, prescribed product.
Know the documented risks Documented trial side effects include nausea (most common), flushing, injection-site reactions, and headache; a transient blood-pressure increase is a labeled concern. Off-label or compounded use in men or outside the approved population is not FDA-evaluated for that use.
These are the trial-documented risks for the approved indication; risk outside that population has not been evaluated the same way.
The FDA approved Vyleesi (bremelanotide) in June 2019 specifically for hypoactive sexual desire disorder in premenopausal women, based on the RECONNECT phase 3 trial program.
View sources
Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (confirms PT-141/Vyleesi's FDA approval for HSDD)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone trying to understand what PT-141 or Vyleesi is actually approved for
- Anyone who has seen PT-141 marketed for general libido enhancement and wants the approved-use boundary
- Patients or caregivers preparing questions for a prescriber
- Readers comparing PT-141 to unregulated “research peptide” versions
Cautions
- Educational only, not medical advice; any decision about a prescription medication belongs with a licensed prescriber.
- The FDA approval covers hypoactive sexual desire disorder in premenopausal women specifically, not general use.
- Compounded or research-chemical “PT-141” sold outside the approved pathway carries the same purity and sourcing concerns as other gray-market peptides.